Iruplinalkib: First Approval-Reference-Cited by-同舟云学术

Iruplinalkib: First Approval

Published:2023-11-27 Issue:18 Volume:83 Page:1717-1721
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Keam Susan J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-023-01970-w.pdf

Reference13 articles.

1. Yang Y, Zheng Q, Wang X, et al. Iruplinalkib (WX-0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. Invest New Drugs. 2023;41(2):254–66.

2. Shi Y, Fang J, Hao X, et al. Safety and activity of WX-0593 (iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022. https://doi.org/10.1038/s41392-021-00841-8.

3. Liu X, Zhang L, Wan H, et al. Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations. Bioorg Med Chem Lett. 2022;66: 128730.

4. Li W, Zhang J, Wang Z, et al. Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. J Natl Cancer Cent. 2021;1(4):123–31.

5. Qilu Pharmaceutical Co Ltd. Iruplinalkib: Chinese prescribing information 2023. https://www.hnysfww.com/mobile/prod.php?code=T040094. Accessed 28 Sep 2023.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring intermolecular interaction between transporter protein, bovine serum albumin and antitumor drug Lorlatinib: Multispectral approaches combined with molecular simulation;Journal of Molecular Structure;2025-02

2. Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come;Journal of Thoracic Oncology;2024-06